
Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
IN VIVO
Start-Up
The RPM Report
Medtech Insight
Sign up
now
|
|

September 21-23, 2009
The Millennium Broadway Hotel • New York City
|
|
|
|
|
Early Bird Special: $200 off until July
15, 2009
Individual
Registration: Reg. $1995
Company Registration: Reg. $1795 3 or more attendees, each
|
|
|
|
|
|
|
It’s THE MOST senior level case studies for dealmaking and strategy available in the industry.
2009 Speakers to date:
Moncef Slaoui
Chairman, Research & Development
GlaxoSmithKline
Dr. Lauren Silverman
Managing
Director Novartis Option Fund
Andrew Dillon, CEO
National Institute for Health
and Clinical Excellence
NICE
Mervyn Turner
SVP, WW Licensing & External Research
Merck and Company
Elliott Sigal
Pres. Pharma Research Institute/C.S.O.
Bristol Myers Squibb
Martin MacKay
President of Pfizer Global Research & Development
Pfizer
Jamie Topper
General Partner
Frazier Healthcare
Can You Be Big and Small at Once?
For at least two decades now, Big Pharma has believed in
the value of big. But they’ve also seen its downside: bureaucratic paralysis,
the burden of growing a substantial top-line, cultural stagnation. And so a
number of companies are now trying to have their cake and eat it, too: adding
capabilities (through acquisitions) and diversifications while creating
therapeutically- or market-focused units capable of making and executing their
own investment decisions independent of the mother ship). This way they’ll have
the advantages of being big (the financial strength to survive major research
and commercial blows, the infrastructure to globally develop and commercialize
new opportunities) and small (speed, focus and entrepreneurial excitement). The
19th annual PSA will explore the implications and inherent contradictions of
this new bifurcated strategy, how and why companies are pursuing it (or not
pursuing it) and its likely effects on biotech and on dealmaking in general.
Benchmark your corporate strategies against the best and the brightest.
Topics include:
2009 Topics Include:
|
Financing Pharma: Creative Ways Companies Are Funding Risk
Even the biggest companies now have to make
lots of choices about what to develop and commercialize. Private equity looked,
for a time, to be an interesting source of capital – but that’s apparently
disappeared. But some biotechs and pharmas have crafted some interesting
potential solutions to the dilemma.
Can emerging markets fill in pharma’s revenues/growth gap?
A review of alliances and acquisitions in
emerging markets with a follow-on panel representing specific deals made.
Corporate VC: Encouraging innovation…creating optionality.
As biotechs’ financing options dwindle,
corporate VC becomes a much more powerful business development tool. Along with
the equity they purchase, pharma can now get options on products – the ability
to pay for assets once they’ve got real evidence of their value. But oddly
enough, corporate VC deals are also looking good for the founding investors,
providing likelier exits with still-substantial returns.
In-Licensing from Established Pharma: Has It Worked?
The remarkable turnaround approval of Vanda’s
iloperidone highlights a still-popular but hardly proven strategy – in-licensing
drug-company development-stage cast-offs. But while a number of in-licensers
have seen good investor returns by selling their companies before their products
have been approved, it’s relatively rare to find start-ups who have successfully
developed in-licensed products. So does the strategy work? Should companies
pursue it – and when?
The pieces of health-care reform that really matter to biopharma.
It’s big, it’s complex, lots of it doesn’t
apply to your job – but key parts will change how you’ll choose among R&D
candidates and then how you’ll develop and commercialize them. We’ll pick apart
the reform proposals to show where and how they’ll be important to you.
-
Follow-on biologics: How the rules will play out in the
market – and how they’ll affect innovator drugs and innovator strategies.
-
Evidence required: Cost effectiveness? Comparative
effectiveness? What evidence will FDA, CMS, NICE and other policy groups and
payers require from you to get your products to market – and paid for.
|
Win is simply where you will meet the most important people in the business.
Who will you meet?

-
Meet your potential partner and find out how to approach them
Meet your potential partner and find out how to approach them
-
Understand externalization models and see if your approach fits your potential partner's positioning
-
Benchmark your dealmaking strategy against what your competitors are doing and why
-
Learn the deal values and deal specifics that let you calibrate deal-making metrics
Maximize your strategic alliance opportunities by hearing CEOs, senior R&D and senior business development executives share lessons learned, practical advice and strategies on how to build your R&D pipeline – both internally and externally. Take away the newest strategies and tactics that you can apply to your company’s dealmaking efforts immediately!
And this September, PSA offers you an unbeatable line-up of Big Pharma and biotech speakers to forecast trends and analyze changes in alliances and M&A. You’ll hear from, and be able to quiz, top industry executives and dealmakers.
PSA gathers top thinkers to grapple with the fundamental challenges facing biotech and pharma – equipping dealmakers like you with the insights, information and practical advice you'll need to strike successful deals. This program will sell out so register early. Space is limited, so register today!
BEYOND THE BASICS! PSA attracts THE most straAnd as always, you’ll be able to network and exchange ideas with an elite group of your peers, your colleagues, your partners and your competitors.
What your colleagues and competitors have to say about Pharmaceutical Strategic Alliances:
|
"Definitely worthwhile. Speakers focused on topics and insights, not on company promotion."
m>"Definitely worthwhile. Speakers focused on topics and insights, not on company promotion."
"Good opportunity to listen to various industry viewpoints regarding the state of pharmaceutical partnering process and outcomes."
"For a first time attendee I found the meeting extremely well-planned and informative."
"Excellent topic coverage, as well as representation of speakers."
"Interesting, relevant topics for the most part and good networking opportunities."
"I attend every year. The content is always engaging."
"One of the 'most attended' conferences, as always."
"The entire agenda is well thought-out and covers several very pertinent topics."
"Great chance to network with leading business development professionals in the industry and share collaboration ideas."
"One of the conferences that I learn something of value."
"A good review of what is going on at the pharma and biotech industries with a brilliant strategic analysis. Excellent selection of speakers and particiapants at the round table discussions."
"I appreciate Windhover conferences. Your organization is one of the few that is trying to understand the pharma/biotech industry in a strategic context."
"Overall, I was pleasantly surprised, it was an excellent meeting and exceeded my expectations because of the quality of attendees."
"It was very good, the presentations and networking opportunities were excellent."
|
|
|
 |
|
|
|
|
| |
 |
Pfizer's Ambitions in the Off-Patent World
The pending purchase of Wyeth will accelerate Pfizer's transformation from a mass marketer of superstar drugs into a . . .[MORE
. . .] (IN VIVO)
The Epigenetics (R)evolution
Constellation and EpiZyme are poised to become dominant players in the unfolding field of epigenetics, an area of biology . . . [MORE. . .] (Start-Up)
A New Era Dawns in Physician-Device Industry Relationships
The push for transparency in the health care industry has moved beyond initial regulations focused on hospital safety . . .[MORE. . .] (Medtech Insight)
The Cost-Sharing Solution: The New NICE Ticket
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that . . .[MORE. . .] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|